## IN THE CLAIMS

This is a complete and current listing of the claims, marked with status identifiers in parentheses. The following listing of claims will replace all prior versions and listings of claims in the application.

- 1. (Previously Presented) A test kit for detecting periodontal disease in a patient by analysing a sample from the oral cavity of the patient, comprising:
- a first detection assay for detecting a first substance originating from bacteria; and
- a second detection assay for detecting a second substance originating from at least one of an immune and an inflammatory system of the patient.
- 2. (Previously Presented) A test kit according to claim 1, wherein said first detection assay comprises at least a first affinity ligand having a binding site for binding said first substance originating from bacteria, and

said second detection assay comprises at least a second affinity ligand having binding site for binding said second substance originating from at least one of an immune and an inflammatory system of the patient.

- 3. (Previously Presented) A test kit according to claim 1, wherein said first substance is a bacterial virulence product.
- 4. (Original) A test kit according to claim 3, wherein said first substance is an enzyme.
- 5. (Original) A test kit according to claim 4, wherein said enzyme is a protease.
- 6. (Original) A test kit according to claim 5, wherein said protease is selected from the group consisting of arg-gingipain from *Porphyromonas gingivalis* and a 48 kDa protease from *Bacteroides forsythus*.

- 7. (Original) A test kit according to claim 3, wherein said first substance is a toxin.
- 8. (Original) A test kit according to claim 7, wherein said toxin is a leukotoxin from Actinobacillus actinomycetemcomitans.
- 9. (Previously Presented) A test kit according to claim 1, wherein said second substance is a leukocyte product.
- 10. (Original) A test kit according to claim 9, wherein said leukocyte product is a natural serine protease.
- 11. (Original) A test kit according to claim 10, wherein said natural serine protease is a human neutrophil elastase.
- 12. (Previously Presented) A test kit according to claim 1, wherein said second substance is a cytokine.
- 13. (Original) A test kit according to claim 12, wherein said cytokine is an interleukin.
- 14. (Original) A test kit according to claim 13, wherein said interleukin is chosen from among interleukin- $1\beta$ , interleukin-6 and interleukin-8.
- 15. (Original) A test kit according to claim 12, wherein said cytokine is an inflammatory mediator.
- 16. (Original) A test kit according to claim 15, wherein said inflammatory mediator is selected from the group consisting of tumour necrosis factor- $\alpha$  and prostaglandin  $E_2$ .
- 17. (Previously Presented) A test kit according to claim 2, wherein said first affinity ligand is a first antibody exhibiting selective binding of said first substance

Docket No. 10400-000091/US/NPB

and said second affinity ligand is a second antibody exhibiting selective binding of said second substance.

- 18. (Original) A test kit according to claim 17, wherein each of said first and second detection assays provides an immunochromatographic assay.
- 19. (Previously Presented) A test kit according to claim 1, further comprising a support provided with a sample reservoir for receiving said sample, wherein said first and second detection assays are arranged on said support in contact with said sample reservoir, directly or via a removably arranged separating means which separates said sample reservoir from said detection assays.
- 20. (Previously Presented) A test kit according to claim 1, further comprising additional buffers for dilution and adaptation of said sample for said detection assays.
- 21. (Original) A test kit according to claim 20, further comprising a buffer reservoir separate from said sample reservoir.
- 22. (Previously Presented) A test kit according to claim 1, further comprising at least one sampling device for obtaining said sample.
- 23. (Previously Presented) The use of a test kit according to claim 1 for detecting periodontal disease.
- 24. (Previously Presented) A method for at least one of diagnosing periodontal diseases and predicting a risk for progress of periodontal diseases, said method comprising:

analyzing a sample from an oral cavity of a patient for a presence of at least a first substance originating from bacteria and a presence of a second substance originating from at least one of an immune and an inflammatory system of the patient.

25. (Original) A method according to claim 24, wherein said first substance is a bacterial virulence product.

- 26. (Previously Presented) A method according to claim 25, wherein said first substance is an enzyme.
- 27. (Original) A method according to claim 26, wherein said enzyme is a protease.
- 28. (Original) A method according to claim 27, wherein said protease is selected from the group consisting of arg-gingipain from Porphyromonas gingivalis and a 48 kDa protease from Bacteroides forsythus.
- 29. (Original) A method according to claim 25, wherein said first substance is a toxin.
- 30. (Original) A method according to claim 29, wherein said toxin is a leukotoxin from Actinobacillus actinomycetemcomitans.
- 31. (Previously Presented) A method according to claim 24, wherein said second substance is a leukocyte product.
- 32. (Original) A method according to claim 30, wherein said leukocyte product is a natural serine protease.
- 33. (Original) A method according to claim 32, wherein said natural serine protease is a human neutrophil elastase.
- 34. (Previously Presented) A method according to claim 24, wherein said second substance is a cytokine.
- 35. (Original) A method according to claim 36, wherein said cytokine is an interleukin.
- 36. (Original) A method according to claim 35, wherein said interleukin is chosen from among interleukin-1β, interleukin-6 and interleukin-8.

- 37. (Original) A method according to claim 36, wherein said cytokine is an inflammatory mediator.
- 38. (Original) A method according to claim 37, wherein said inflammatory mediator is selected from the group consisting of tumour necrosis factor- $\alpha$  and prostaglandin  $E_2$ .
- 39. (Previously Presented) A method according to claim 24, wherein said analyzing comprises analyzing said sample with a first method that selectively detects the presence of said first substance and a second method that selectively detects the presence of said second substance.
- 40. (Original) A method according to claim 39, wherein said first method comprises using a first antibody exhibiting selective binding of said first substance and wherein said second method comprises using a second antibody exhibiting selective binding of said second substance.
- 41. (Original) A method according to claim 40, wherein at least one of said first and second methods comprises using an immunochromatographic assay.